McGuireWoods and McGladrey are pleased to host our 11th Annual Healthcare & Life Sciences Private Equity & Finance Conference on February 25th and 26th at The Ritz-Carlton in Chicago. We are honored to have as our primary key note speaker political analyst and
private
Private Equity Opportunities in Contract Research Organizations (CROs): Part II
In Part II of this blog series we look at recent transactions in the arena of contract research organization, with a particular focus on private equity investing in CROs.
In one recent example, prescription drug data-mining company IMS Health acquired…
Continue Reading Private Equity Opportunities in Contract Research Organizations (CROs): Part II
Private Equity Opportunities in Contract Research Organizations (CROs): Part I
Contract research organizations (CRO) provide research services support for the biotechnology, medical device and pharmaceutical industries on a contractual basis. They offer such services as preclinical and clinical research, clinical trials management, biopharmaceutical development and pharmacovigilance. CROs run the gamut …
Continue Reading Private Equity Opportunities in Contract Research Organizations (CROs): Part I
Dental Investing Filling Need for PE Investing – Part II
During recent months, private equity firms have been actively selling and buying dental practices, which some investors believe is a relatively stable and recession-proof health-care arena. With an aging population requiring more dental work, minimal government intervention and mostly private-pay…
Continue Reading Dental Investing Filling Need for PE Investing – Part II
Dental Investing Filling Need for PE Investing – Part I
Dental practice management companies have been an increasing focus of private equity firms throughout the United States and Canada. As the cost of healthcare increases, small dental practices, like private medical practices, will soon be an anomaly. Thus, it is…
Continue Reading Dental Investing Filling Need for PE Investing – Part I
Private Equity Investing in the Dialysis Sector – Part III (Overseas Investing)
As we round out our series on private equity investing in dialysis, we note an emergence in overseas dialysis investing by U.S. investors. Our blog typically focuses on U.S. investing but can’t help but note the interest in overseas…
Continue Reading Private Equity Investing in the Dialysis Sector – Part III (Overseas Investing)
Private Equity Investing in the Dialysis Sector – Part II
Part II of our series on private equity investing in dialysis discusses other dialysis companies backed by private equity and highlights some key considerations for investors and companies.
Funded in 2000, U.S. Renal Care (USRC), is another dialysis company…
Continue Reading Private Equity Investing in the Dialysis Sector – Part II
Private Equity Investing in the Dialysis Sector – Part I
Private equity investors have been active in the dialysis sector for decades. In Part I of this series on dialysis investments, we describe the recent emergence of three companies with private equity backing.
First, in 2010 Bain Capital …
Continue Reading Private Equity Investing in the Dialysis Sector – Part I
McGuireWoods Announces 9th Annual Healthcare & Life Sciences Private Equity & Finance Conference
The healthcare and life science markets are in a period of dramatic change.
Despite this change, successful private equity funds can still execute deals and achieve capital growth by implementing the right strategies in the right markets. Join us at …
Value-Based Healthcare Solutions: A Prescription for Investors in an Era of Healthcare Reform
A few weeks ago, McGuireWoods hosted our 8th Annual Healthcare & Life Sciences Private Equity & Finance Conference along with co-sponsor McGladrey. The Hon. Bill Frist gave the keynote address. It was a real treat to…